New pill could ease severe postpartum depression in just 3 days
NCT ID NCT06285916
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 34 times
Summary
This study tested an experimental oral drug called NORA520 in 93 women with severe postpartum depression. Participants took the drug or a placebo for 3 days. Researchers measured how well it reduced depression symptoms, checked for side effects, and looked at how much of the drug gets into breastmilk. The goal is to see if NORA520 is a safe and fast way to help new mothers feel better.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSTPARTUM DEPRESSION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Advanced Research Center
Anaheim, California, 92805, United States
-
Alliance Research Institute
Canoga Park, California, 91304, United States
-
CenExel Clinical Research
Decatur, Georgia, 30030, United States
-
CenExel Clinical Research
Savannah, Georgia, 31405, United States
-
Cenexel Clinical Research
Sherman Oaks, California, 91403, United States
-
Cenexel Clinical Research
Torrance, California, 90504, United States
-
Cenexel Clinical Research
Atlanta, Georgia, 30331, United States
-
Clinical Research Center of Florida
Pompano Beach, Florida, 33060, United States
-
Combined Research
Orlando, Florida, 32807, United States
-
GCP Research
St. Petersburg, Florida, 33607, United States
-
Insight Hospital and Medical Center Chicago
Chicago, Illinois, 60616, United States
-
Maximos Ob/Gyn
League City, Texas, 77573, United States
-
MedOne Clinical Research
Miami, Florida, 33145, United States
-
Meridian International Research, Inc.
Miami Gardens, Florida, 33014, United States
-
Monroe Biomedical Research
Monroe, North Carolina, 28112, United States
-
Pillar Clinical Researc
Richardson, Texas, 75080, United States
-
Pillar Clinical Research
Bentonville, Arkansas, 72712, United States
-
Zucker Hillside Hospital
Glen Oaks, New York, 11004, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NORA520
What this could lead to
If it works, this could provide a fast-acting, short-course oral treatment for severe postpartum depression, helping new mothers recover more quickly.
What could go wrong
This is a small Phase 2 trial with only 93 participants, so results may not apply to all women. The treatment is only 3 days long, and side effects or lack of effectiveness are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.